Regulatory leadership STI Pharma shows recent turnover in VP Regulatory Affairs & Product Development, indicating ongoing regulatory initiatives and potential need for accelerated approval support, dossier optimization, and compliance consulting for oncology injectables.

Oncology focus Specialization in oncology and injectables suggests opportunities for high-value sterile product development, late-stage formulation enhancements, and contract manufacturing for high-margin cancer therapies.

Growth potential Revenue in the mid tens of millions with a small employee base implies opportunities for scalable partnerships, outsourced manufacturing arrangements, and software-enabled operations to support rapid expansion.

Digital footprint Tech stack includes QuickBooks, iCIMS, Squarespace, WordPress, and analytics tools, signaling openness to vendor partnerships for ERP optimization, CRM recruitment support, and digital marketing or regulatory submission software integration.

Leadership transition Past leadership appointments and recent executive moves indicate a window for strategic BD outreach around licensing, co-development, or distribution agreements aligned with a growing oncology portfolio.